Generative AI for regulated industries: where to start, what to avoid

Regulated-industry leaders face a specific version of the GenAI adoption problem: the business case is clear, the board is asking questions, and the compliance team has circled every risk on a whiteboard. The result, too often, is paralysis dressed up as diligence. This guide offers a structured way out—use case selection criteria, a tiered risk framework, and a list of deployment pitfalls drawn from what has actually gone wrong in financial services, healthcare, and public sector rollouts.

1. Before you start: what must be in place

2. The right way to tier your use cases

Not all GenAI use cases carry the same regulatory exposure. A tiering approach—based on who sees the output and what decisions it influences—is more useful than a blanket risk rating for the technology itself. The three tiers below map to increasing levels of required controls, not to a timeline for when to deploy them.

3. Where to start: high-value, lower-risk use cases by sector

The use cases below have demonstrated early traction in regulated environments because they pair meaningful productivity gains with contained risk profiles. Each sits in Tier A or Tier B by default—meaning a trained employee reviews the output before it affects a regulated decision.

Financial services

1. Regulatory change summarization. Ingests new guidance (SEC releases, Basel updates, FCA consultations) and produces a structured impact summary for compliance teams. Reduces manual reading time; a human analyst validates the summary before it reaches the business.
2. Loan and credit memo drafting. Pulls from structured application data and internal credit policy documents to draft the narrative section of a credit memo. The underwriter edits and approves; the model never makes the credit decision.
3. Call-center knowledge assist. Provides agents with real-time, retrieved answers from internal policy documents during live calls. Customer hears the agent, not the model; output is advisory.
4. SAR narrative drafting. Flags structurally suspicious transaction patterns and drafts a Suspicious Activity Report narrative for a BSA officer to review and file. Reduces drafting time; the officer retains filing authority.
5. Vendor contract redline summarization. Summarizes vendor contract deviations from standard terms for legal and procurement review. Does not execute or approve contracts.

Healthcare

1. Clinical documentation assist. Converts physician dictation or ambient audio into structured draft notes for EHR entry. The clinician reviews and signs; the model produces a draft, not a final record.
2. Prior authorization letter drafting. Drafts the clinical justification letter for prior auth submissions using relevant patient history and clinical guidelines. A care manager reviews before submission.
3. Patient discharge summary generation. Produces a structured draft discharge summary from clinical notes. Reduces administrative time at end of episode; physician signs the final document.
4. Internal policy Q&A for clinical staff. Allows nurses and pharmacists to query internal formulary, protocol, and policy documents in natural language. Retrieval is scoped to approved documents only.
5. Coding assist for revenue cycle. Suggests ICD and CPT codes from clinical documentation for a coder to review. Does not submit claims autonomously.

Public sector

1. Constituent inquiry drafting. Produces draft responses to high-volume citizen inquiries (benefits questions, permit status) for a case worker to review and send. Reduces response time without removing human approval.
2. Policy document summarization. Converts dense legislative or regulatory text into plain-language summaries for internal staff briefings. Reviewers validate accuracy before distribution.
3. Procurement document review. Flags deviations from standard terms in vendor RFP responses and contract drafts. A contracting officer retains decision authority.
4. Training content generation. Drafts updated training materials when policy changes. Instructional designers review before publication.
5. Internal knowledge search. Allows staff to query across legacy policy repositories and procedure manuals in natural language. Scoped retrieval limits exposure to approved, versioned documents.

4. What to avoid: the failure modes that matter most

The pitfalls below are specific to regulated environments. Generic AI failure modes—hallucination, prompt injection, model drift—matter here too, but the following are the ones that produce regulatory findings, not just embarrassing errors.

• Deploying a Tier C use case with Tier A controls. Customer-facing or decision-triggering deployments require adversarial testing, explainability, and often a pre-deployment regulatory notification. Skipping these because the underlying model 'performed well' in internal testing is the most common source of enforcement attention.
• Treating retrieval scope as a technical detail. What a RAG system is allowed to retrieve is a governance decision, not an engineering one. Allowing the model to retrieve from unsanctioned data sources—even accidentally—can produce outputs that cite non-current policy, confidential internal guidance, or information the user was not authorized to see.
• No model versioning clause in vendor contracts. Foundation model providers update models on their own schedules. Without a contractual freeze or notification requirement, a model update can change output behavior in a workflow that has already passed your validation process.
• Conflating 'human in the loop' with 'human review'. A human who rubber-stamps 500 AI-generated outputs per shift is not providing meaningful review. Regulators are beginning to ask for evidence that human reviewers have the time, training, and authority to actually override the model.
• Starting with the most complex use case. The instinct to show impact leads teams toward Tier C deployments—autonomous customer interactions, real-time decisioning—before the governance infrastructure exists to support them. Start with Tier A use cases, build the audit and monitoring stack, and promote use cases up the tier ladder as controls mature.

5. Vendor evaluation: what to ask in demos

The vendor landscape for regulated-industry GenAI spans foundation model providers, enterprise platform vendors with compliance modules, and specialized point solutions for healthcare documentation or financial compliance. The questions below apply across all three categories.

• Show me the audit log. What exactly is captured—prompt text, retrieved chunks, model version, response, and user identity? Can I export it in a format my regulator accepts?
• How do you handle model version changes? Will I receive advance notice before a base model update? Can I pin to a specific model version for a defined period?
• What is your data retention policy? Does prompt or response data leave my environment? Where is it stored, for how long, and under what conditions can your team access it?
• How do you scope retrieval in a RAG deployment? Can I enforce document-level or role-level access controls on what the model is allowed to retrieve?
• What hallucination rate can you demonstrate on a domain-specific evaluation set? Ask them to run it on your documents, not on a generic benchmark.
• What is your incident response process if the model produces a harmful or non-compliant output in production? How quickly can the deployment be paused or rolled back?
• Do you have customers in production in my sector? Ask for a reference call with a compliance or risk officer at a comparable organization—not just an engineering contact.

6. Sizing the governance investment

Teams that underinvest in governance infrastructure early tend to hit a scale ceiling: the first one or two use cases work, but each new deployment requires a bespoke review process because there is no shared framework. The formula below is a rough planning heuristic, not a budget template.

7. Building the internal coalition

The most common organizational failure in regulated-industry GenAI is not technical—it is the gap between the team that wants to deploy and the team that owns the controls. A compliance officer who learns about a GenAI deployment from a vendor demo rather than from the project team is a compliance officer who will block the deployment. Build the coalition early.

• Bring legal and compliance in at use case selection, not at sign-off. Their input shapes the tier assignment and the required controls; involving them late means redesign, not approval.
• Give the risk team a named role on the deployment team. Not a reviewer—a participant. They need to understand what the model does in order to assess what it might do wrong.
• Create a shared definition of 'production-ready'. Engineering, compliance, and the business unit should agree in writing on what evidence is required before a use case moves from pilot to scale.
• Establish a standing AI risk review cadence. A quarterly review of deployed use cases—covering output quality, audit log anomalies, and any near-misses—is more sustainable than ad-hoc escalation.

8. Next steps